



Supplementary Figure 8. Analysis of intracellular cytokine changes in antigen-specific or ConA driven response, data presented as a frequency difference normalized to healthy controls. (a, b) CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets from splenocytes of EAE animals treated *in vivo* daily from onset with vehicle, nalfurafine (0.01mg/kg) or U50,488 (1.6 mg/kg). (c, d) CD4<sup>+</sup> and CD8<sup>+</sup> T cell freq from splenocytes of MOG35-55 immunized animals to day 28, and treated with vehicle (0.01% DMSO), nalfurafine (50 nM) or U50,488 (1 μM) for 72 hours alongside stimulations. (e, f) Analysis of CD4<sup>+</sup> and CD8<sup>+</sup> T cell intracellular IL-10 following *in vivo* KOR agonist treatment as MFI. (g) CD8<sup>+</sup> T cell intracellular IL-17A (as frequency of parent, CD8<sup>+</sup>) following *in vivo* KOR agonist treatment (h) CD8<sup>+</sup> T cell intracellular IL-17A (as frequency of parent, CD8<sup>+</sup>) following *in vitro* KOR agonist treatment, \*P<0.05, \*\*\*P<0.001 by 1-way ANOVA with Holm-Sidak's multiple comparison test. Data are mean ± SEM.